Your session is about to expire
← Back to Search
Roadmap 2.0 for Quality of Life in Cancer Caregivers and Patients
N/A
Waitlist Available
Led By Sung Won Choi, MD, MS
Research Sponsored by University of Michigan Rogel Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 120
Awards & highlights
Study Summary
This trial will study how well a mobile app (Roadmap 2.0) and Fitbit help caregivers of cancer patients. The goal is to see if using the app is feasible and acceptable.
Eligible Conditions
- Cancer
- Quality of Life
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 120
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 120
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Enrollment rate
Roadmap 2.0 login rate
Secondary outcome measures
Survey completion rate
Trial Design
1Treatment groups
Experimental Treatment
Group I: Roadmap 2.0 + Fitbit Charge 3Experimental Treatment3 Interventions
Caregivers and patients download the Roadmap 2.0 mobile app on their own mobile phones or tablet to use freely throughout the 120 day study period.
Caregivers and patients receive a Fitbit wearable activitiy sensor to track activity and sleep.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Roadmap 2.0 information system
2020
N/A
~140
Find a Location
Who is running the clinical trial?
University of Michigan Rogel Cancer CenterLead Sponsor
293 Previous Clinical Trials
23,959 Total Patients Enrolled
Sung Won Choi, MD, MSPrincipal InvestigatorUniversity of Michigan Rogel Cancer Center
4 Previous Clinical Trials
3,223 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Roadmap 2.0 + Fitbit Charge 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger